Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai Aspires to Become World Top Innovator Post-COVID-19 Era: President
July 7, 2020
- Maviret Shrivels, but AbbVie Japan in “Growth Mode” with Oncology, Immunology Drivers: Chief
July 3, 2020
- GSK Japan Sets Up Women’s Leadership Initiative to Bring Diversity in Managerial Ranks
July 3, 2020
- Daiichi Sankyo Adds Patients with Triple Negative Breast Cancer into PI DS-1062 Study
July 3, 2020
- Nobelpharma Launches European Subsidiary in Germany
July 3, 2020
- Fujifilm Inks Global Avigan Deal with Dr. Reddy’s, Global Response Aid
July 2, 2020
- Nippon Shinyaku, Torii to Invest in New Biotech Funds
July 2, 2020
- Tolerability of Telomelysin for HCC Confirmed in PI: Oncolys
July 2, 2020
- Eisai’s Eritoran to Enter Clinical Study for COVID-19 on Global Platform
July 2, 2020
- Towa Comarkets Celltrion’s Remicade Biosimilar in Japan
July 2, 2020
- Aspen Japan to Take Over Anti-Anxiety Med Lexotan
July 2, 2020
- AstraZeneca Taps Celgene Exec as New R&D Head
July 2, 2020
- 26 Japan Drug Makers Log 4% Fall in Workforce as Downtrend Continues Unabated: FY2019 Securities Reports
July 1, 2020
- Rakuten Medical’s Photoimmunotherapy Filed in Japan, Subject to Conditional Early OK
July 1, 2020
- Shionogi, StemRIM Extend Collaboration for “Regeneration-Inducing Medicine”
July 1, 2020
- Chugai Files Polatuzumab Vedotin for DLBCL in Japan
July 1, 2020
- Otsuka, Axcelead Link Up for Drug Discovery in CNS Field
July 1, 2020
- Nichi-Iko to Suspend Supply of Olmesartan OD Tab. 20 mg as COVID-19 Cripples API Procurement
July 1, 2020
- AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
- Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…